Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

Summary

The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.

Timeline

Start

2024-11-06

Primary completion

2026-02-23

Completion

2026-02-23

Outcome

Outcome not reported

Stopped (Enrollment): “Low enrollment status”

Drugs

Indications